cfan:e CIAN HEALTHCARE LIMITED (A n 9001:201 5 & WHO GMP Certified co.) To, BSE Limited - CRD P.J. Towers, Dalai Street, Fort, Corporate Otfice: Floor, Premdeep Building, Atnve Latur urban Co-op Bank Ltd.. Lulla Nagar Chowk. Camp Kondhwa Road, Pune - 411 040. (Maharashtra) INDIA, Tel: 491-20-41471234 Email: [email protected], [email protected]Web: wwwcian.co Registered Office: Milkat from South Side. C,S_ No 227/10 3B. Harpal* Park. Berger Paint, Phursungi, Tal Haveli, DiSt - 412 3C8, (uaharashtra) INDIA. Tele.Fax.: Kh- NO_: 248. Village Sisona, Bhagwanpur. Roorkee, 'Eridwar. Pin • 247 661. Utarakhand. Tel: 1332 235352 CIN: L24233PN2003PLC017563 Date: 13.11-2020 Script code: 542678 sub: SUBMISSION OF HALF YEARLY UNAUDITED FINANCIAL RESULTS FOR THE HALF YEAR SOT" SEPTEMBER. 2020 AS PER REGULATION 33 OF SEBJ (LODR) REGULATIONS. 2015. Dear Sir(s), pursuant to Regulation 33 Of SEBI (LODR) Regulations, 2015, we are pleased to submit the Unaudited Financial Results (Standalone and Consolidated) for the Half year 3(P' 2020 in the form of PDF which was also approved by the Audit Committee and the Board Of Directors Of the Company at their meeting held on Friday, 13th November, 2020. We are in process to file the aforesaid financial results in the form of XBRL within the stipulated time of 24 hours from the conclusion of the board meeting and the same shall also be hosted at the website of the Company. You are requested to take on the Unaudited Financial Results along With Limited Review Report for your reference and record. Thanking You, Yours Faithfully, For Cian Healthcare Limited Suraj S Managi DIN: ni Encls: Unaudited Financial Results and Limited Review Report.
sub: SUBMISSION OF HALF YEARLY UNAUDITED FINANCIAL RESULTS FOR THE HALF YEARSOT"SEPTEMBER. 2020AS PER REGULATION 33 OF SEBJ(LODR) REGULATIONS. 2015.
Dear Sir(s),
pursuant to Regulation33 Of SEBI (LODR) Regulations,2015, we are pleasedto submit the Unaudited FinancialResults(StandaloneandConsolidated)for theHalfyear 3(P' 2020in theformof PDFwhichwasalsoapprovedby theAudit CommitteeandtheBoardOfDirectorsOftheCompanyat their meetingheldonFriday,13th November, 2020.
We are in processto file the aforesaid financial results in the form of XBRL within the stipulatedtime of 24hoursfrom theconclusionof the boardmeeting andthe sameshall alsobehostedat the websiteof the Company.
You are requestedto take on the Unaudited Financial Results along With Limited Review Report for yourreference and record.
Thanking You,
Yours Faithfully,
For Cian Healthcare Limited
Suraj SManagiDIN:
ni
Encls: Unaudited Financial Results and Limited Review Report.
19.Agarwal Mahesh K. & Co.Chartered Accountants
HealthcareLimited pursuant to the Regulation33 Of the SEBI(ListingObligations and DisclosureRequirements) Regulations, 201S
The Of DirectorsCian Healthcare Limited
We have reviewed the statement of unaudited standalone financial results Of CianHealthcareLimited •theCompany') for the half year endedSeptember 30, 2020and for the year-to-dateresultsfor the period frorn April I, 2020 to September30,2020 ('the Statement'), being submitted bytheCornpanvpursuant to the requirements of Regulation33 Of the Securitiesand ExchangeBoard of India(ListingObligationsandDisclosureRequirements)Regulations,2015asamended('theRegulation').
ThisStatementis the responsibilityOftheCompany'sManagementandh" beenapprovedbytheBoardOfdirectorsandstatementhas preparedin "cordanceWiththe recognitionandmeasurgmentprinciples laid down in AS 25 'Interim Finandal Reporting', under Section 133 Of the
Act, 2013 read with relevant rules issuedthere under and other rec%nizedaccountingprinciplesgenerallyacceptedin India.Our responsibilityis to expressa conclusionon the Statementbased on our review.
Weconductedour reviewOfthe statementin acmrdancewith theStandardon ReviewEnmements(SRE)2410 "Reviewof Interim FinancialInformationperformed by the IndependentAuditor Of theEntity",issuedby the Instituteof CharteredAccountantsof India.Thisstandardrequiresthat we planandperformthe review to obtain moderateassuranceas to whether the financial statementsare free Ofmaterialmisstatement.A reviewis primarilyto inquiriesOfcompany andanalytical
applied to financial data and thus provide less assurance than an audit. We have notan audit and accordingly, we do not express an audit opinion.
Based our reviewconductedas nothinghascorneto our attention that causesus to Believethattheaccompanyingstatementof unauditedfinancialresultspreparedinaccordancewithapplicableaccounting standardsandotherrecognizedaccountingpracticesandpolicies,hasnot disclosedtheinformationrequiredto bedisclosedin termsof Regulation33of theSEBI(ListingObligationsandDisclosureRequirements)Regulations,201SincludingthemannerinWhichit isto disclosed,orthatitcontains any material misstatement.
7. The StatusOf Investors Complaints during the half year ended on 30.09.2020 is asunderpending at the beginning Of the above period: NILReceived during the above NILDisposed during the above 'Eriod: NILRemaining unsolved at the end of the NIL
8. Figuresofprcvious year/Periodhavebeenregrouped/re•äßtedwherevernecessary.in orderto makethemcomparable.9. The companyisprimarily engagedin thebusinessOfPharmacuticals•whichis single reportablesegmentfor thehalf yeÜ/ yearended30.092020 henceno separate
Place:Punc
as AS-17
for CianHealthcareLimited
• PUNE •
CIAN HEALTHCARE LIMITED
MILKAT NO.3J39, BLOCK NO.' FROM SOUTH SIDE.cs.N0.227/2+3A,HARPALE PARK,OPP.BERGER PAINT
STATEMENT OF STANDALONE CASHFIÅ)W AS AT 30.09.2020
Cash Flow from operating activitksNet Profit aner tax
Adjusunent
Depreciation andamortizÄiOn(Profit) / LOSS Of
Tax L iabdityO'*rating profit working Changes
(Irxrease)/ in OtherNon Currentasset(Increase) / Decreasein Inventories(Increase) \ Decreasein Trade receivables(Increase) / Decreasein Other Cunent Assets(Increase) Decreasein Deferred Tax Asset(Increase) Decreasein other financialIncrease / in provisions
/ Financial Liabilities/ShCRt
in Ck.ferred tax liabilities
Cash generated from operatkms
Tax—paidNet cash operating activitks
Cash now from activities
of fixed assets
proceedsfrom saleof fixed assets'Subsidy/ in Capital
Interest & Dividard received
Purchases of Shares of Dr. Smiths Biotech Private Ltd.
Proceeds/ (Repayment)of OtherFinancialAssetsNet Cash from investing activities
Cash now from nuancing activitksproceedsfrom issumceof ShMeq'ital including sharepremiumproceeds from long term btrrowingsproceeds\ from / Of borrowings
from ShareApplicOn MoneyDivicknd paid dbtrthution tax
/ (Repayment) FInterest paidNet from Financing Activitiø
Increase I (Decrease) cash and cash equivalentsCashandcashequivalentsat of the yearCash and cash uivalents at end of the r
l. WehavereviewedtheaccompanyingStatementOfunauditedeonwlZatedfinancialresultsOfCianHealthcareLimited("the Parent")andits-subsidiary(the Parentandits subsidiarytogetherreferredto as"the Group"),and its shareof the net profit after tax for the half yearended
2020 and year to date results for the from 01 April 2020 to 302020 Cthe Statement'), being submitted by the Parent pursuant to the requirements ofRegulation33 Of the SEBI(ListingObligationsand DisclosureRequirements) Regulations,2015,asamerxiedCListingRegulations').
2. This Statement. which the of the Parenes management and awoved by theParent's Board of Directors, has been prepared in accordance with the recognition and
principles laid down in Accounting Standard 25 "Interim Financial ("AS25"), under Section 133Ofthe CompaniesAct, 2013, and Other accounting principks
Kcepted in India and in compliancewith Regulation33 Of the Listing Regulations.Ourresponsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Staternent in accordarxe with on RevkwEruements (SRE)2410 "ReviewOf Interim FinancialInformation performedby theIndependent Auditor of the Entity-. issued by the Institute of Chartered Accountants of India Areviewof interim financialinformationconsistsof making inquiries,primarilyofresponsiblefor financialand accountingminers. andapplyinganalyticaland other rev•wpnxedures. A review is substantially less in scopethan an audit conducted in Kcordance withStandardson Auditirwand consequentlydæs not enableus to obtain assurancethat we would
awareofallsignificantmattersthatmightbeidentifiedinanaudit.Accordingly,wedonot expressan audit opinion.We alsoRrformed prxxeduresin accordarxewith the circularissuedbytheSEBIunderRegulation33(8)oftheListingRegulations,totheextentapplicable.
6. We did not review the interim financialresultsandother financial information of subsidiaryincludedin the Statement,whoseinterimfinancialresultsand other financialinformationreflectstotalassetsof Rs2325.09lakhsasat30September2020andtotal revenuesof Rs47.79lakhs,total net lossafter tax OfRs.144.39lakhs,for the half yearended30 %ptember 2020,and cashoutflows (net) of Rs.30.20lakhsfor the from 01 April 2020 to 30September2020, as considered in the consolidated unaudited financial results. These interim financialresults and Other financial information havebeen reviewed by Other auditor whose hasbeenfurnishedto usbythe managementandourconclusionon the Statement,in farasitrelatesto the amountsanddisclosuresincludedin respectof the subsidiary,is basedsolelyonthe report of the other auditor andthe proceduresperformedby usas stated in paragraph3above.Our conclusionon the Statement is not modified in respect of the atnve matters.
For Agarwal Mahesh K. & Co.Accountants
FRN o
CASunny Boundia
FRN:
No. 164172
Date: 13.11.2020
UDIN:- 20164172AA.a.ABA8%8
LLMITED
MILKAT SOUN SIDE.
CAN PARK.OPP. b ERG ER FAINT
STATEMENT OF CONSOLIDATED PROFIT AND LOSS m R HALF YEAR ENDED ON
CONTINUING OPERATIONS
MAT
DISCONTIN OPERATIONS
31, 2020
71201
2.9"29
n.iiz 12.iii)
I. Ihe AboveFinancialResultsandStaten-rentof AssetsandLiabilitieswerepreparedasperAccountingStamiardsandreviewedby•tCommitteeandthenapprovedby theBoardof Directorsat their resp:ctivemeetingsheld on 13thNovember,2020
. •IheResultsfor thehalfyearendedon30thSeptember,2020areauditedby theStatutoryAuditorsof thecompanyin complianceWiththe regulation33 of SEBI (LODR) Regulations,20153. The Earing Per Share(EPS) hasbeen computed in accordancewith the AS-204. Thc consolidated accounts havebeen prepared asper AS-215. List OfSubsidiary ason 3(hh September2020
Name Of the Entity ; Dr. Smiths Biotech Private LimitedRealtionship SubsidiaryCountry of Incorporation : India% of Ownership : 100%
6.Other Income fortheyearendedOn30.09.2020includesInterestoniixedDepo•sites,Incomefrorn benefits&OtherMisc.
7. TheStatusoflnvestors Complaintsduring thehalf yearendedon 30.09.2020is asunderPendingat thebeginningorthe period:NILReceived during the above NILDisposed during the above period: NILRemaining unsolved at the end of the NIL
STATEMENT OF CONSOLIDATED CASHFLOW AS AT 30.09.2020
Cash Flow from 01krating activitiesNet profit tax
A for:
(Profit) / on Sale,'D1sposaIof assetsInterest EWisesInterest & Dividend received
Dcfcrrcd Tax LiabilityOperating profit before working capital Changes
(Increase) / tkcrewe in Non Current asset
(Increase) / in receivables(Increase) / Decreoe in Other Current Assets(Increase) Decreasein Deferred Tax Asset(Increase) \ Decreasein other financial assetsIncrease/ (Decrease) in Provisions
/ in
Increase/ (Decreoe) in Other Financial Liabilities,Short Term BcrrowingIncrease/ (Decrease) in Deferred tax liabilitiesIncrease/ (Decreax) in Other Current Liabiliti•
generated from
axespaidNet cashfrom operating activities
Cash from
Of fixed
from sale of fixed
(Increze) Decreasein CapitalWork in ProgresInterest & Dividend recened
Of Of Smiths Biotech private Ltd.
/ Of Other F
Net now from ities
Cash now from nnancing activitiesfrcunissuanceof ShareCapital including sharepremium
Proceeds from long term borrowings/ (Rcpaynwnt) / of term (Above)
ApplicationDividend paid including dividend distribution tax
/ Other Financial Assets
Interest paidNet Cash from Financing Activities
Increase / (Decrease) in cash and cash equivalentsand cashequivalents at txginning of thc year
